Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28358485 | 0.90 | TSHR (0.49) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL15461584 | 0.85 | TSHR (0.61) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL13812467 | 0.83 | TSHR (0.59) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL3754233 | 0.82 | TSHR (0.58) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL3754232 | 0.82 | TSHR (0.58) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL639511 | 0.81 | ALDH1A1 (0.55) | TSHRALDH1A1LMNAHTTMAPT | |
| SCHEMBL2372535 | 0.81 | ALDH1A1 (0.65) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL14842559 | 0.81 | FABP4 (0.50) | TSHRALDH1A1LMNAHTTMCOLN3 | |
| SCHEMBL22116653 | 0.80 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTHPGDMEN1 | |
| SCHEMBL50817 | 0.80 | ALDH1A1 (0.54) | TSHRALDH1A1LMNAHTTMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1476151-B1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ORGANON NV (NL) | 2008-07-16 | — | — | EP | disclosed |
| US-7049468-B2 | Modulators of Rho C activity | ICONIX PHARMACEUTICALS, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| EP-1453470-A4 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARM INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | MERCK SHARP & DOHME B.V. (NL) | 2005-07-14 | — | — | US | disclosed |
| EP-1476151-A1 | 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Akzo Nobel N.V. (NL) | 2004-11-17 | — | — | EP | disclosed |
| EP-1453470-A1 | MODULATORS OF RHO C ACTIVITY | Iconix Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | ENTELOS HOLDING CORP. | 2003-09-11 | — | — | US | disclosed |
| WO-2003068220-A1 | 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | AKZO NOBEL N.V. (NL) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003043578-A2 | MODULATORS OF RHO C ACTIVITY | ICONIX PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171341-A1 | Method for modulating the activity of a Rho C enzyme, comprising: contacting said Rho C enzyme with an effective amount of a compound of formula 1: | RHOC, RHOA, ROCK1 | TSHR 2816/4885ALDH1A1 1730/4885LMNA 1844/4885 |
| US-20050154023-A1 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | TPH1, HTR1A, HTR1D | TSHR 613/4885ALDH1A1 1048/4885LMNA 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.